US Patent Issued to Alnylam Pharmaceuticals on June 17 for "Coagulation factor V (F5) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,297, issued on June 17, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Coagulation factor V (F5) iRNA compositions and methods of use thereof" was invented by Mark Keating (Weston, Mass.), James D. McIninch (Burlington, Mass.) and Mark K. Schlegel (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the Coagulation Factor V (F5) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an F5 gene and to methods of treating or preventing an F5-associated disease, e.g., a disorder associated with thrombosis, in a subjec...